Predicting Response to Pregabalin from Pretreatment Pain Quality: Clinical Applications of the Pain Quality Assessment Scale

Pain Medicine (United States)

Volumn 14, Issue 4, 2013, Pages 526-532

  Gammaitoni, Arnold R ^a   Smugar, Steven S ^a   Jensen, Mark P ^b   Galer, Bradley S ^c   Bolognese, James A ^d   Alon, Achilles ^a   Hewitt, David J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Nuvo Research Inc   (United States)

^d Cytel Incorporated   (United States)

Author keywords

Diabetic Neuropathy; Neuropathic Pain; Neuropathy; Pain Assessment; Pain Quality; Pain Quality Assessment Scale; Pregabalin; Response

Indexed keywords

GABAPENTIN; PLACEBO; PREGABALIN;

ACCURACY; ARTICLE; DIABETIC NEUROPATHY; DRUG DOSE ESCALATION; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN QUALITY ASSESSMENT SCALE; POST HOC ANALYSIS; POSTHERPETIC NEURALGIA; SENSITIVITY AND SPECIFICITY; SENSORY NEUROPATHY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALGESICS; ETHNIC GROUPS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84876175332     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01423.x     Document Type: Article

References (24)

1. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:1-9.
2. Huskisson EC, Woolf DL, Balme HW, Scott J, Franklin S. Four new anti-inflammatory drugs: Responses and variations. Br Med J 1976;1:1048-9.
3. Preston SJ, Arnold MH, Beller EM, Brooks PM, Buchanan WW. Variability in response to nonsteroidal anti-inflammatory analgesics: Evidence from controlled clinical therapeutic trial of flurbiprofen in rheumatoid arthritis. Br J Clin Pharmacol 1988;26:759-64.
4. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs-Differences and similarities. N Engl J Med 1991;324:1716-25.
5. Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: Implications for therapeutic substitution in ambulatory patients. DICP 1989;23:76-85.
6. Bingham CO III, Smugar SS, Wang H, Tershakovec AM. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology (Oxford) 2009;48:1122-7.
7. Battisti WP, Katz NP, Weaver AL, etal. Pain management in osteoarthritis: A focus on onset of efficacy-A comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511-20.
8. Dougados M, Gueguen A, Nakache JP, etal. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year vs a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
9. Bingham CO III, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: Pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo. Pain Med 2011;12:352-61.
10. Bradley JD, Katz BP, Brandt KD. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 2001;28:1073-6.
11. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78.
12. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:332-8.
13. Jensen MP, Dworkin RH, Gammaitoni AR, etal. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain 2005;6:98-106.
14. Jensen MP, Gammaitoni AR, Olaleye DO, etal. The pain quality assessment scale: Assessment of pain quality in carpal tunnel syndrome. J Pain 2006;7:823-32.
15. Jensen MP, Dworkin RH, Gammaitoni AR, etal. Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning? J Pain 2006;7:644-53.
16. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain 2006;22:97-103.
17. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic vs non-neuropathic pain. J Pain 2007;8:118-26.
18. Victor TW, Jensen MP, Gammaitoni AR, etal. The dimensions of pain quality: Factor analysis of the Pain Quality Assessment Scale. Clin J Pain 2008;24:550-5.
19. Gould EM, Jensen MP, Victor TW, etal. The pain quality response profile of oxymorphone extended release in the treatment of low back pain. Clin J Pain 2009;25:116-22.
20. Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain 2009;25:286-92.
21. Hewitt DJ, Ho TW, Galer B, etal. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 2010;152:514-21.
22. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
23. Jensen MP, Gammaitoni A, Bolognese J, etal. The pain quality response profile of pregabalin in the treatment of neuropathic pain. Clin J Pain 2011 Dec 7 [Epub ahead of print]. doi: 10.1097/AJP.0b013e31823f9e64.
24. Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J Rheumatol 2001;28:2494-503.